HCPLive

Long-Acting Clotting Agent Approved for Form of Hemophilia

MONDAY, March 31, 2014 (HealthDay News) -- The drug Alprolix has been approved by the US Food and Drug Administration (FDA) as the first long-acting hemophilia B clotting agent, the FDA said in a news release.

The product, formally known as "coagulation factor IX recombinant Fc Fusion protein" is the first hemophilia B remedy designed to require less frequent injections than prior treatments, the FDA said. It was approved to help control and prevent bleeding episodes and to manage bleeding during surgery.

Alprolix was evaluated in clinical studies involving 123 people, ages 12-71, with severe hemophilia B. No safety issues were identified during the trials, the FDA said.

The product is manufactured by Biogen Idec, located in Cambridge, Mass.

More Information


Copyright © 2014 HealthDay. All rights reserved.

Most Popular

Recommended Reading

A recent study looked into the neural functions affected by ibuprofen and found some connections that may soon lead to a much greater understanding of the greatest pain mitigator of them all: the brain.
Researchers from the University of California-Santa Barbara recently announced they have created an implantable “artificial pancreas” that could potentially eliminate the need for insulin injections and pumps for treating type 1 diabetes.
Discontinuation of multiple sclerosis medication saw nearly 2 in 5 patients experience some form of increased disease activity, according to research from NYU Langone Medical Center.
As more research is done the more it appears brown fat will play a key role in the future treatment of diabetes.
$vAR$